Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

state of florida doh central pharmacy - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir sulfate 600 mg - epzicom tablets, in combination with other antiretroviral agents, are indicated for the treatment of hiv-1 infection. additional important information on the use of epzicom for treatment of hiv-1 infection: - epzicom is one of multiple products containing abacavir. before starting epzicom, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir. - in one controlled study (cna30021), more patients taking ziagen 600 mg once daily had severe hypersensitivity reactions compared with patients taking ziagen 300 mg twice daily. - as part of a triple-drug regimen, epzicom tablets are recommended for use with antiretroviral agents from different pharmacological classes and not with other nucleoside/nucleotide reverse transcriptase inhibitors. see warnings, adverse reactions, and description of clinical studies. there have been no clinical trials conducted with epzicom (see clinical pharmacology for informa

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

physicians total care, inc. - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir sulfate 600 mg - epzicom tablets, in combination with other antiretroviral agents, are indicated for the treatment of hiv-1 infection. additional important information on the use of epzicom for treatment of hiv-1 infection: - epzicom is one of multiple products containing abacavir. before starting epzicom, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir. - in one controlled study (cna30021), more patients taking ziagen 600 mg once daily had severe hypersensitivity reactions compared with patients taking ziagen 300 mg twice daily. - as part of a triple-drug regimen, epzicom tablets are recommended for use with antiretroviral agents from different pharmacological classes and not with other nucleoside/nucleotide reverse transcriptase inhibitors. see warnings, adverse reactions, and description of clinical studies. there have been no clinical trials conducted with epzicom (see clinical pharmacology for informa

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

state of florida doh central pharmacy - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir sulfate 300 mg - ziagen tablets and oral solution, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (hiv-1) infection. additional important information on the use of ziagen for treatment of hiv-1 infection: - ziagen is one of multiple products containing abacavir. before starting ziagen, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir. ziagen is contraindicated in patients with previously demonstrated hypersensitivity to abacavir or any other component of the products. never restart ziagen or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of hla-b*5701 status [see warnings and precautions (5.1), adverse reactions (6)] . ziagen is contraindicated in patients with moderate or severe hepatic impairment. pregnancy category c. studies in pregnant rats showed that abacavir is transferred to the fe

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

state of florida doh central pharmacy - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - abacavir 300 mg - trizivir is indicated in combination with other antiretrovirals or alone for the treatment of hiv-1 infection. additional important information on the use of trizivir for treatment of hiv-1 infection: trizivir tablets are contraindicated in patients with: trizivir: pregnancy category c. there are no adequate and well-controlled studies of trizivir in pregnant women. reproduction studies with abacavir, lamivudine, and zidovudine have been performed in animals (see abacavir, lamivudine, and zidovudine sections below). trizivir should be used during pregnancy only if the potential benefits outweigh the risks. abacavir: studies in pregnant rats showed that abacavir is transferred to the fetus through the placenta. fetal malformations (increased incidences of fetal anasarca and skeletal malformations) and developmental toxicity (depressed fetal body weight and reduced crown-rump length) were observed in rats at a dose which produced 35 times the human exposure, based on auc. embryonic and fetal toxicities (incre

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

avera mckennan hospital - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 300 mg

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

viiv healthcare company - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 300 mg - ziagen tablets and oral solution, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (hiv-1) infection. ziagen is contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ziagen during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the general population. the macdp evaluates women and infants from a limited geographic area and does not include outcomes for births that occurred at less than 20 weeks’ gestation. the rate of misca

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

remedyrepack inc. - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir 600 mg - epzicom, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection. epzicom is contraindicated in patients: - who have the hla‑b*5701 allele [see warnings and precautions ( 5.1)] . - with prior hypersensitivity reaction to abacavir [see warnings and precautions ( 5.1)] or lamivudine. - with moderate or severe hepatic impairment [see use in specific populations ( 8.7)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to epzicom during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

viiv healthcare company - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir 600 mg - epzicom, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection. epzicom is contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to epzicom during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the general population. the macdp evaluates women and infants from a limited geographic area and does not include outcomes for births that occurred at less than 20 weeks’ gestation. the rate of miscarri

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

viiv healthcare company - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - abacavir 300 mg - trizivir is indicated in combination with other antiretrovirals or alone for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection. limitations of use: trizivir is contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to trizivir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir, lamivudine, or zidovudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the general population. the macdp evaluates women and infants from a limited geographic area and does not include outcomes for births that occurred at less than 20 w

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

avera mckennan hospital - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 300 mg